BERIPLEX P/N 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
Active substance(s): FACTOR II / FACTOR IX / FACTOR VII / FACTOR X / HUMAN PROTHROMBIN COMPLEX / PROTEIN C / PROTEIN S
Package leaflet: Information for the user
250, 500 and 1000 IU
Powder and solvent for solution for injection
Human prothrombin complex
Read all of this leaflet carefully before you start using this medicine
because it contains important information for you.
• Keep this leaflet. You may need to read it again.
• If you have further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others. It
may harm them, even if their signs of illness are the same as yours.
• If you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. See section 4.
What is in this leaflet
1. What Beriplex is and what it is used for
2. What you need to know before you use Beriplex
3. How to use Beriplex
4. Possible side effects
5. How to store Beriplex
6. Contents of the pack and further information
What Beriplex is and what it is used for
What is Beriplex?
Beriplex is presented as powder and solvent. It is a white or slightly coloured
powder or friable solid. The made up solution is to be given by injection into a vein.
Beriplex is made from human plasma (this is the liquid part of the blood) and it
contains the human coagulation factors II, VII, IX and X. Concentrates including
these coagulation factors are called prothrombin complex products. The
coagulation factors II, VII, IX and X are vitamin K-dependent and are important for
blood clotting (coagulation). Lack of any of these factors means that blood does
not clot as quickly as it should and so there is an increased tendency to bleed. The
replacement of factors II, VII, IX and X with Beriplex will repair the coagulation
What is Beriplex used for?
Beriplex is used for the prevention (during surgery) and treatment of bleedings
caused by the acquired or congenital lack of vitamin K-dependent coagulation
factors II, VII, IX and X in the blood, when purified specific coagulation factor
products are not available.
What you need to know before you use Beriplex
The following sections contain information that your doctor should consider before
you are given Beriplex.
Do NOT use Beriplex:
• if you are allergic to any of the active substances or other ingredients of this
medicine (listed in section 6).
Please inform your doctor if you are allergic to any medicine or food.
• if you are more likely to suffer from blood clots than normal (patients at risk of
disseminated intravascular coagulation)
• if you show an allergic response to heparin, causing a fall in the number of
blood platelets (heparin-induced thrombocytopenia Type II, HIT Type II).
Please inform your doctor or pharmacist if you suffer from such a
F3777 G28 A
Warnings and precautions
Talk to your doctor or pharmacist before using Beriplex in case of:
• Acquired deficiency of the vitamin K-dependent coagulation factors:
This may be induced by treatment with medicines inhibiting the vitamin K effect.
Beriplex is only allowed to be used when rapid correction of the prothrombin
complex levels is necessary, e.g. in case of major bleedings or emergency surgery
• Congenital deficiency of any of the vitamin K-dependent factors:
In this case you should use specific coagulation factor products when available
• Allergic or anaphylactic-type reactions (a serious allergic reaction that causes
severe difficulty in breathing or dizziness):
The application of Beriplex should be stopped immediately (e.g.
• Increased risk of formation of blood clots in a blood vessel (thrombosis),
– if you have had a heart attack (a history of coronary heart disease or
– if you suffer from liver disease
– if you have just had surgery (patients per- or postoperatively)
– in new-born infants (neonates)
– if you are more likely to suffer from blood clots than normal (patients at risk
of thromboembolic phenomena or disseminated intravascular coagulation or
simultaneous inhibitor deficiency)
• Increased coagulation risk due to increased consumption of blood platelets or
blood coagulation factors. Treatment with Beriplex can only be started after
treatment of the underlying cause.
• Reduced development of blood platelets due to heparin (heparin-induced
thrombocytopenia, HIT Type II). Heparin, a protein with a blood clot dissolving
effect, is an ingredient of Beriplex. The severe form of a decrease in blood
platelets may be associated with
– blood clots in the vein or leg,
– an increased formation of blood clots,
– in some cases with skin rash where the injection was given,
– pinpoint-sized haemorrhages and
– tarry stool.
In these cases the effect of heparin may be diminished (heparin tolerance).
If these symptoms occur, you should stop using the product immediately and
contact your doctor. In the future no heparin-containing products should be used.
• A special form of inflammation of the kidneys has been reported after treatment
of patients who suffer from haemophilia B with factor IX inhibitors. These
patients were also known to have a history of allergic reaction.
Your doctor will consider carefully the benefit of treatment with Beriplex compared
with the risk of these complications.
When medicines are made from human blood or plasma, certain measures are put
in place to prevent infections being passed on to patients. These include:
• careful selection of blood and plasma donors to make sure those at risk of
carrying infections are excluded, and
• the testing of each donation and pools of plasma for signs of virus/infections,
• the inclusion of steps in the processing of the blood or plasma that can
inactivate or remove viruses.
Despite these measures, when medicines prepared from human blood or plasma
are administered, the possibility of passing on infection cannot be totally excluded.
This also applies to any unknown or emerging viruses or other types of infections.
The measures taken are considered effective for enveloped viruses such as human
immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the
non-enveloped hepatitis A and parvovirus B19 viruses.
Your doctor may recommend that you consider vaccination against hepatitis A and
B if you regularly/repeatedly receive human plasma-derived prothrombin complex
It is strongly recommended that every time you receive a dose of Beriplex, the
name and batch number of the medicine are recorded in order to maintain a record
of the batched used.
The following information is intended for healthcare professionals
Qualitative and quantitative composition
Beriplex nominally contains the following IU of the human coagulation factors
Name of the
Content after Beriplex P/N
reconstitution 250 content
per vial (IU)
per vial (IU)
per vial (IU)
20 – 48
200 – 480
400 – 960
800 – 1920
10 – 25
100 – 250
200 – 500
400 – 1000
20 – 31
200 – 310
400 – 620
800 – 1240
22 – 60
220 – 600
440 – 1200
880 – 2400
15 – 45
150 – 450
300 – 900
600 – 1800
12 – 38
120 – 380
240 – 760
480 – 1520
The total protein content is 6 – 14 mg/ml of reconstituted solution.
The specific activity of factor IX is 2.5 IU per mg total protein.
The activities of all coagulation factors as well as Protein C and S (antigen) have
been tested according to the current valid international WHO-Standards.
Posology and method of administration
Only general dosage guidelines are given below.
The amount and the frequency of administration depends on the indication for
treatment and should be calculated on an individual patient basis. Dosage intervals
must be adapted to the different circulating half-lives of the respective coagulation
factors in the prothrombin complex. Individual dosage requirements can only be
identified on the basis of regular determinations of the individual plasma levels of
the coagulation factors of interest, or on global tests of the prothrombin complex
levels (INR, Quick’s test), and a continuous monitoring of the clinical condition of
In case of major surgical interventions, precise monitoring of the substitution
therapy by means of coagulation assays is essential (specific coagulation factor
assays and/or global tests for prothrombin complex levels).
• Bleeding and perioperative prophylaxis of bleedings during vitamin K
The dose will depend on the INR before treatment and the targeted INR. The pretreatment INR should be measured as close as possible to the time of dosing in order
to calculate the appropriate dose of Beriplex. In the following table approximate
doses (ml/kg body weight of the reconstituted product and IU Factor IX/kg b.w.)
required for normalisation of INR (e.g. ≤ 1.3) at different initial INR levels are
2.0 – 3.9
4.0 – 6.0
Approximate dose ml/kg body weight
Approximate dose IU (Factor IX)/kg
Dose is based on body weight up to but not exceeding 100 kg. For patients
weighing more than 100 kg the maximum single dose (IU of Factor IX) should
therefore not exceed 2500 IU for an INR of 2.0 – 3.9, 3500 for an INR of
4.0 – 6.0 and 5000 IU for an INR of > 6.0.
The correction of the vitamin K antagonist-induced impairment of haemostasis is
commonly reached approximately 30 minutes after the injection. The simultaneous
administration of vitamin K should be considered in patients receiving Beriplex for
urgent reversal of vitamin K antagonists since vitamin K usually takes effect within
4 – 6 hours.
Repeated dosing with Beriplex for patients requiring urgent reversal of vitamin K
antagonists treatment is not supported by clinical data and therefore not
• Bleedings and perioperative prophylaxis in congenital deficiency of
any of the vitamin K-dependent coagulation factors when specific
coagulation factor products are not available.
The calculation of the required dosage of prothrombin complex concentrate is
based on data from clinical studies:
• 1 IU of factor IX per kg body weight can be expected to raise the plasma factor IX
activity by 1.3 % (0.013 IU/ml) of normal
• 1 IU of factor VII per kg body weight raises the plasma factor VII activity by 1.7 %
(0.017 IU/ml) of normal
• 1 IU of factor II per kg body weight raises the plasma factor II activity by 1.9 %
(0.019 IU/ml) of normal
• 1 IU of factor X per kg body weight raises the plasma factor X activity by 1.9 %
(0.019 IU/ml) of normal.
The dose of a specific factor administered is expressed in International Units (IU),
which are related to the current WHO standard for each factor. The activity in the
plasma of a specific coagulation factor is expressed either as a percentage (relative
to normal plasma) or in International Units (relative to the international standard
for the specific coagulation factor).
One International Unit (IU) of a coagulation factor activity is equivalent to the
quantity in one ml of the normal human plasma.
For example, the calculation of the required dosage of factor X is based on the
finding that 1 International Unit (IU) of factor X per kg body weight raises the
plasma factor X activity by 0.019 IU/ml.
The required dosage is determined using the following formula:
Required units = body weight [kg] x desired factor X rise [IU/ml] x 53
where 53 (ml/kg) is the reciprocal of the estimated recovery.
Note that the calculation is based upon data from patients receiving vitamin K
antagonists. A calculation based upon data from healthy subjects would provide a
lower estimate of the required dose.
If the individual recovery is known, that value should be used for calculation.
Product specific information is available from clinical studies in healthy volunteers
(N = 15), in reversal of vitamin K antagonist treatment for acute major bleeding or
perioperative prophylaxis of bleeding (N = 98, N = 43).
The safety and efficacy of Beriplex in children and adolescents has not yet been
established in controlled clinical studies (see section 4.4).
The posology and method of administration in older people (>65 years) is
equivalent to the general recommendations.
Method of administration
– The solution should be clear or slightly opalescent. After filtering/withdrawal
(see below) reconstituted product should be inspected visually for particulate
matter and discoloration prior to administration. Do not use solutions that are
cloudy or have deposits.
– Reconstitution and withdrawal must be carried out under aseptic conditions.
Bring the solvent to room temperature. Ensure product and solvent vial flip caps
are removed and the stoppers are treated with an antiseptic solution and allowed
to dry prior to opening the Mix2Vial package.
1. Open the Mix2Vial package by peeling off the lid. Do not
remove the Mix2Vial from the blister package!
2. Place the solvent vial on an even, clean surface and hold
the vial tight. Take the Mix2Vial together with the blister
package and push the spike of the blue adaptor end
straight down through the solvent vial stopper.
3. Carefully remove the blister package from the Mix2Vial set
by holding at the rim and pulling vertically upwards.
Make sure that you only pull away the blister package and
not the Mix2Vial set.
The reconstituted solution should be administered intravenously (not more than
Any unused medicinal product or waste material should be disposed of in
accordance with local requirements.
Special warnings and precautions for use
No data are available regarding the use of Beriplex in case of perinatal bleeding
due to vitamin K deficiency in neonates.
4. Place the product vial on an even and firm surface. Invert
the solvent vial with the Mix2Vial set attached and push
the spike of the transparent adaptor end straight
down through the product vial stopper. The solvent will
automatically flow into the product vial.
Notes for control of platelet count:
Platelet count should be closely monitored.
Interaction with other medicinal products and other forms of interaction
When performing clotting tests which are sensitive to heparin in patients receiving
high doses of human prothrombin complex, the heparin as a constituent of the
administered product must be taken into account.
5. With one hand, grasp the product-side of the Mix2Vial set,
and with the other hand grasp the solvent-side and
unscrew counterclockwise the set carefully into two
Discard the solvent vial with the blue Mix2Vial adaptor
* in Beriplex clinical trials patients weighing <70 kg were instructed to be dosed
with a maximum infusion speed of 0.12 ml/kg/min (less than 8 ml/min)
Other medicines and Beriplex
• Tell your doctor or pharmacist if you are taking, have recently taken or might
take any medicines.
• Beriplex may inhibit the effect of vitamin K antagonist treatment. No
interactions with other medicinal products are known.
• This medicinal product must not be mixed with other medicinal products except
those mentioned in section 6.
Pregnancy, breast-feeding and fertility
• If you are pregnant or breast-feeding, think you may be pregnant or planning to
have a baby, ask your doctor or pharmacist for advice before taking any medicine.
• During pregnancy and breast-feeding Beriplex should be given only if it is clearly
• No fertility data are available.
Driving and using machines
No studies on the effects on the ability to drive and use machines have been
Beriplex contains sodium
Beriplex contains up to 343 mg sodium (approximately 15 mmol) per 100 ml.
Please take this into account if you are on a controlled sodium diet.
How to use Beriplex
Treatment should be started and supervised by a physician who is experienced in
this type of disorder.
The amount of Factor II, VII, IX and X you need will depend on several factors, such
as your body weight, the severity and nature of your disease, the site and intensity
of the bleeding or the need to prevent bleeding during an operation or investigation
(see section “The following information is intended for healthcare professionals
If you have any further questions on the use of this medicine, ask your doctor or
6. Gently swirl the product vial with the transparent adaptor
attached until the substance is fully dissolved. Do not
7. Draw air into an empty, sterile syringe. While the product
vial is upright, connect the syringe to the Mix2Vial's Luer
Lock fitting by screwing clockwise. Inject air into the
Your doctor should regularly check your blood clot status during the treatment.
High doses of prothrombin complex concentrate have been associated with
instances of heart attack, disseminated intravascular coagulation and an increased
formation of blood clots in a blood vessel in patients at risk of these complications.
Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody
The following side effects have been observed commonly (may affect up to 1 in
• There is a risk of formation of blood clots (see section 2)
• Increase in body temperature
Withdrawal and application
8. While keeping the syringe plunger pressed, turn the
system upside down and draw the solution into the syringe
by pulling the plunger back slowly.
The following side effects occurred uncommonly (may affect up to 1 in
• Hypersensitivity or allergic reactions (see section 2)
How to store Beriplex
• Keep this medicine out of the sight and reach of children.
• Do not use this medicine after the expiry date, which is stated on the label and
• Do not store above 25 °C.
• Do not freeze.
• Keep the vial in the outer carton, in order to protect from light.
• Beriplex does not contain a preservative, so the made-up solution should
preferably be used immediately.
Contents of the pack and other information
What Beriplex contains:
Beriplex 250 IU contains 200 – 310 IU human coagulation factor IX per vial.
Beriplex 500 IU contains 400 – 620 IU human coagulation factor IX per vial.
Beriplex 1000 IU contains 800 – 1240 IU human coagulation factor IX per vial.
The active substance is:
A concentrate of the human coagulation factors II, VII, IX and X, Proteins C and S.
The other ingredients are:
Human antithrombin III, heparin, human albumin, sodium chloride, sodium citrate,
HCl or NaOH (in small amounts for pH adjustment)
Solvent: Water for injections
What Beriplex looks like and contents of the pack
Beriplex is presented as a white or slightly coloured powder and is supplied with
water for injections as solvent. The powder should be dissolved with 10 ml (250 IU),
20 ml (500 IU) or 40 ml (1000 IU) of water for injections.
The made-up solution should be clear or slightly opalescent, i.e. it might sparkle
when held up to the light but must not contain any obvious particles.
One pack with 250 IU containing:
– 1 vial with powder
– 1 vial with 10 ml water for injections
– 1 filter transfer device 20/20
One pack with 500 IU containing:
– 1 vial with powder
– 1 vial with 20 ml water for injections
– 1 filter transfer device 20/20
One pack with 1000 IU containing:
– 1 vial with powder
– 1 vial with 40 ml water for injections
– 1 filter transfer device 20/20
Marketing Authorisation Holder and Manufacturer
CSL Behring GmbH
This leaflet was last revised in 10/2014.
The frequency of the following side effects is not known (cannot be estimated
from the available data)
• Excessive coagulation resulting in severe bleeding
• Anaphylactic reactions including shock (see section 2)
• Formation of circulating antibodies inhibiting one or more coagulation factors
9. Now that the solution has been transferred into the
syringe, firmly hold on to the barrel of the syringe (keeping
the syringe plunger facing down) and disconnect the
transparent Mix2Vial adaptor from the syringe by
No data are available regarding the use of Beriplex in the paediatric population.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any
possible side effects not listed in this leaflet. You can also report side effects directly
via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of
Care should be taken that no blood enters the syringe filled with product, as there
is a risk that the blood could coagulate in the syringe and fibrin clots could
therefore be administered to the patient.
In case more than one vial of Beriplex is required, it is possible to pool several vials
of Beriplex for a single infusion via a commercially available infusion device.
The Beriplex solution must not be diluted.
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.